
Low-risk meningioma: Outcomes from NRG 0539
Dr. Jasmin Jo interviews Dr. Leland Rogers about his and his team's recent manuscript entitled: "Low-risk meningioma: initial outcomes from NRG Oncology/RTOG 0539", published online in Neuro-Oncology ...
29 Heinä 202220min

Selumetinib in children with NF1 and plexiform neurofibroma
Dr.Iyad Alnahhas interviews Drs. Andrea Gross and Brigitte Widemann about their manuscript entitled "Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofi...
1 Heinä 202223min

Targeted therapy for BRAF-mutant pediatric glioma
Dr. Evan Noch interviews Drs. Kee Kiat Yeo and Matthias Karajannis about their recent manuscript entitled: "Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high grade gli...
17 Kesä 202223min

Early/evolving IDH wild-type glioblastoma
Description: Dr. Maya Graham interviews Dr. David Solomon about his and his team's recent manuscript entitled: "Prospective genomically-guided identification of "early/evolving" and "undersampled" IDH...
20 Touko 202224min

PI3K signaling in IDH mutant gliomas
Dr. Evan Noch interviews Dr. Joanna Phillips about her and her team manuscript entitled: "PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications", published on...
6 Touko 202224min

Cell-free DNA from CSF in pediatric, adolescent and young adult patients
Dr. Iyad Alnahhas interviews Dr. Matthias Karajannis about his and his team's recent manuscript entitled: "Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pedia...
22 Huhti 202210min

Molecular determinants of neurocognitive deficits in glioma
Dr. Ankush Bhatia interviews Dr. Emma van Kessel about her and her team's recent manuscript entitled "Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma", ...
8 Huhti 202218min

H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma
Dr. Iyad Alnahhas interviews Dr. Carl Koschmann about his and his team's recent manuscript entitled: "Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progre...
25 Maalis 202222min











